Dare Bioscience, Inc. cash flow to debt ratio of -372.21% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Dare Bioscience, Inc.'s free cash flow has decreased -313.04% from $4.82M last year to $-10.27M, signaling decreasing performance

Dare Bioscience, Inc.'s debt to equity ratio is 2.20, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Dare Bioscience, Inc.'s debt has increased relative to shareholder equity from -0.22 last year to 2.20 today, signaling weakened financials

Dare Bioscience, Inc. has negative EBITDA, making leverage ratio unreliable

Dare Bioscience, Inc.'s interest coverage ratio is -25.58, which means that the company struggles to meet interest obligations, signaling financial risk.

Dare Bioscience, Inc.'s profit margin has increased (-97.49%) in the last year from -41.43K% to -1.04K%, signaling increasing performance

Dare Bioscience, Inc.'s short-term assets of $27.06M exceed its short-term liabilities of $23.69M

Dare Bioscience, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Dare Bioscience, Inc.'s return on equity of 763.44%, is higher than 15.00%, indicating good performance

Dare Bioscience, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Dare Bioscience, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Dare Bioscience, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Dare Bioscience, Inc. has negative free cash flow, indicating cash burn

Dare Bioscience, Inc.'s yearly earnings has decreased 230.55% since last year from $-4.05M to $-13.40M, signaling decreasing performance

Dare Bioscience, Inc.'s yearly revenue has increased 10.53M% since last year from $9.78K to $1.03G, signaling increasing performance

ROIC -151.41% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Dare Bioscience, Inc.'s 3-year revenue CAGR of -53.12% is negative, indicating declining revenue over the past 3 years

Dare Bioscience, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Dare Bioscience, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Dare Bioscience, Inc. is undervalued relative to its fair value price of 1.89K based on Discounted Cash Flow model

Dare Bioscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dare Bioscience, Inc. is undervalued relative to its fair value price of 2.31K based on EBITDA multiple model

Dare Bioscience, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Dare Bioscience, Inc. has insufficient data to evaluate this check.

Dare Bioscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dare Bioscience, Inc. has a price-to-book ratio of 40.91x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Dare Bioscience, Inc. has a price-to-sales ratio of 25.97x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue